M. Thirlwell

发表

Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain

N. Hagen, N. Babul, Z. Harsanyi, 1994, Cancer.

Pharmacokinetics and clinical efficacy of oral morphine solution and controlled‐release morphine tablets in cancer patients

J. Stewart, J. Maroun, B. Mount, 1989, Cancer.

Radioembolization for hepatic metastases.

M. Thirlwell, M. Herba, 2002, Seminars in oncology.

Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea

G. Dranitsaris, M. Vincent, S. Dowden, 2007, Current oncology.

Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.

M. Buyse, S. Gill, J. Biagi, 2011, Current oncology.

Eastern Canadian Colorectal Cancer Consensus Conference 2017.

S. Welch, P. Kavan, D. Jonker, 2018, Current oncology.

Steady‐State Pharmacokinetics of Hydromorphone and Hydromorphone‐3‐Glucuronide in Cancer Patients After Immediate and Controlled‐Release Hydromorphone

N. Hagen, N. Babul, Z. Harsanyi, 1995, Journal of clinical pharmacology.

Consensus recommendations for the use of anti-egfr therapies in metastatic colorectal cancer.

H. Kennecke, S. Gill, S. Dowden, 2010, Current oncology.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019

M. Lock, S. Welch, S. Singh, 2021, Current oncology.

Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.

T. Alcindor, R. Rajan, M. Thirlwell, 2013, Anticancer research.

Development of critical appraisal skills in medical students: opportunities in oncology-related learning situations.

M. Thirlwell, H. Shibata, 1991, Journal of cancer education : the official journal of the American Association for Cancer Education.

Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.

W. Shabana, T. Vuong, P. Kavan, 2015, Current oncology.

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

M. Buyse, J. Mackey, N. Robert, 2013 .

Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome

Amin Andalib, T. Alcindor, V. Marcus, 2013, Medical Oncology.

New approaches to measuring nausea g

R. Melzack, Z. Rosberger, M. Thirlwell, 2005 .

Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.

J. Macfarlane, M. Huggins, M. Thirlwell, 1981, Journal of the Canadian Association of Radiologists.

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study

T. Julian, C. Geyer, N. Wolmark, 2014, Breast Cancer Research and Treatment.

Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancers.

C. Giacomantonio, D. Hedley, K. Jhaveri, 2012, Current oncology.

Capecitabine-induced cardiotoxicity: case report and review of the literature

R. Rajan, M. Thirlwell, C. Ang, 2010, Current oncology.

Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.

R. Schilsky, R. Pazdur, M. Thirlwell, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival and Recurrence Patterns after Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) for Locally Advanced Esophagogastric Adenocarcinoma

T. Alcindor, L. Ferri, M. David, 2014, Annals of Surgical Oncology.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

A. Chien, N. Iannotti, C. Barcenas, 2020 .

Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study.

A. Korzun, G. Lesnick, J. Holland, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A rapid in vitro labeling index method for predicting response of human solid tumors to chemotherapy.

R. Livingston, W. Murphy, M. Thirlwell, 1976, Cancer research.

Early results of studies on the levels of depleted uranium excreted by Balkan residents

N. Priest, M. Thirlwell, 2001 .

Hepatic malignancies: improved treatment with intraarterial Y-90.

P. Bret, M. Atri, L. Rosenthall, 1988, Radiology.

Disposition of 5-fluorouracil after intravenous bolus doses of a commercial formulation to cancer patients.

J. Ruedy, D. Sitar, M. Thirlwell, 1977, Cancer research.

Ambulatory hepatic artery infusion chemotherapy for cancer of the liver.

J. Macfarlane, M. Thirlwell, G. Boos, 1986, American journal of surgery.

Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.

T. Alcindor, V. Marcus, L. Ferri, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Mallory‐Weiss tear. A complication of cancer chemotherapy

D. Daly, M. Thirlwell, Marc L. Fishman, 1983, Cancer.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

C. Falkson, R. Burkes, J. Maroun, 2015, Current oncology.

Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease.

J. Villeneuve, S. Welch, D. Jonker, 2010, Current oncology.

Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.

E. Mamounas, A. Brown, S. Anderson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eastern Canadian Colorectal Cancer Consensus Conference: standards of care for the treatment of patients with rectal, pancreatic, and gastrointestinal stromal tumours and pancreatic neuroendocrine tumours.

S. Gill, S. Welch, J. Biagi, 2013, Current oncology.

Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain.

P. Sloan, N. Babul, Z. Harsanyi, 1995, Journal of pain and symptom management.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018.

P. Karanicolas, S. Welch, D. Jonker, 2019, Current oncology.

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

M. Dowsett, T. Julian, M. Cheang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

R. Bose, H. Rugo, C. Singer, 2022, Breast.

Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain.

N. Hagen, J. Eisenhoffer, Z. Harsanyi, 2005, Journal of pain and symptom management.

The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.

P. Frenette, M. Trudeau, M. Thirlwell, 1994, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

New approaches to measuring nausea.

R. Melzack, Z. Rosberger, M. Thirlwell, 1985, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. A study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, B. Weinerman, H. Silver, 1987, British Journal of Cancer.

Phase II study ofhighdoseweekly intravenous humanlymphoblastoid interferon inrenal cell carcinoma A StudyoftheNational CancerInstitute ofCanadaClinical Trials Group

E. Eisenhauer, B. Weinerman, H. Silver, 1987 .

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor – Positive Early Breast Cancer

Maggie, Morden., M. Dowsett, 2019 .

Disposition of 5‐fluorouracil during chronic hepatic arterial infusion to patients with carcinoma in the liver and effect on circulating platelets

J. Ruedy, D. Sitar, M. Thirlwell, 1979, Biopharmaceutics & drug disposition.

New approaches to measuringnauseag

R. Melzack, M. Thirlwell, 1985 .

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

C. Geyer, N. Wolmark, P. Ganz, 2021, NPJ breast cancer.

Neoadjuvant chemotherapy with cytosine arabinoside by continuous infusion and cisplatin for resectable squamous cell carcinoma of the esophagus

G. Batist, D. Mulder, M. Trudeau, 1992, Journal of surgical oncology.

Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: Safety and response results from a multicenter phase II trial.

T. Alcindor, V. Marcus, L. Ferri, 2010 .

Consensus recommendations for the use of anti- egfr therapies

H. Kennecke, S. Gill, S. Dowden, 2010 .

NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).

M. Buyse, T. Julian, S. Paik, 2012 .